Technical Perspectives on Biotech Stocks -- ACADIA Pharma, Achaogen, Achillion Pharma, and Acorda Therapeutics

NEW YORK, April 9, 2018 /PRNewswire/ --

WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on ACAD, AKAO, ACHN, and ACOR which can be accessed for free by signing up to www.wallstequities.com/registration. For today, WallStEquities.com re-explores the Biotech space, whose nature of the operations makes equities in this space more suited to aggressive, risk-tolerant investors. Stock prices here can fluctuate dramatically, particularly in response to news developments concerning the success or failure of a particular drug. Four stocks have been lined up for assessment, and they are: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Achaogen Inc. (NASDAQ: AKAO), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), and Acorda Therapeutics Inc. (NASDAQ: ACOR). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

ACADIA Pharmaceuticals

San Diego, California headquartered ACADIA Pharmaceuticals Inc.'s stock finished last Friday's session 2.71% lower at $21.53. A total volume of 1.13 million shares was traded. The Company's shares are trading below their 50-day moving average by 20.09%. Additionally, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have a Relative Strength Index (RSI) of 36.95. Get the full research report on ACAD for free by clicking below at: www.wallstequities.com/registration/?symbol=ACAD

Achaogen

On Friday, shares in South San Francisco, California-based Achaogen Inc. ended the session 3.80% lower at $12.15. The stock recorded a trading volume of 1.13 million shares. The Company's shares have gained 9.76% in the last month and 3.23% in the previous three months. The stock is trading 6.67% above its 50-day moving average. Moreover, shares of Achaogen, which focusses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant gram-negative infections in the US, have an RSI of 51.85.  

On March 22^nd, 2018, Achaogen announced that on March 20^th, 2018, the compensation committee of its Board of Directors granted eight new employees the option to purchase an aggregate of 41,390 shares of its common stock and 15,025 restricted stock units. Each stock option has an exercise price per share equal to $11.00, which was the closing trading price on March 20^th, 2018. Access the free research report on AKAO now by signing up at: www.wallstequities.com/registration/?symbol=AKAO

Achillion Pharmaceuticals

New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc.'s shares closed the session flat at $3.49 with a total trading volume of 1.06 million shares. The stock has gained 11.50% over the previous three months. The stock is trading 3.51% above their 50-day moving average. Additionally, shares of Achillion Pharma, which discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the US, have an RSI of 44.64. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ACHN at: www.wallstequities.com/registration/?symbol=ACHN

Acorda Therapeutics

Last Friday at the close, shares in Ardsley, New York headquartered Acorda Therapeutics Inc. recorded a trading volume of 335,899 shares. The stock ended the session 0.87% lower at $22.75. The Company's shares have advanced 8.08% over the previous three months and 33.43% over the past year. The stock is trading below its 200-day moving average by 2.40%. Furthermore, shares of Acorda Therapeutics, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 42.10.  

On March 26^th, 2018, Acorda Therapeutics announced that it has submitted a Marketing Authorization Application to the European Medicines Agency for INBRIJA, an investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson's disease taking a carbidopa/levodopa regimen. In addition, the US FDA is currently reviewing a New Drug Application for INBRIJA and has set an action date of October 05^th, 2018, under the Prescription Drug User Fee Act. Aspiring Member, please take a moment to register below for your free research report on ACOR at: www.wallstequities.com/registration/?symbol=ACOR

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities